Merger & Acquisition
Larka is pleased to announce it performed the Commercial Due Diligence for Partners Group—supporting its acquisition of FairJourney Biologics, a leading antibody discovery Contract Research Organization (CRO).
Merger & Acquisition
Larka is delighted to announce it acted as the buy-side Commercial Due Diligence advisor for Motion Equity Partners—supporting its acquisition of Banook, a leading French Central Service Provider.
Tech Ops & Outsourcing
Leveraging Lensource®, Larka enabled the identification and selection of CRO, CDMO and CMO partners for 4 major Biotech & Pharma clients, including...
Tech Ops & Outsourcing
Juvisé Pharmaceuticals leveraged Larka’s Lensource® solution for the identification, assessment and selection of a Contract Manufacturing Organisation (CMO) partner to supply one of its commercial products.
Merger & Acquisition
Larka is delighted to announce it acted as the sell-side Vendor Commercial Due Diligence provider to support the sale process of Biose Industrie—a world-leading Contract Development and Manufacturing Organisation (CDMO)—acquired by L-GAM & the French State.
Merger & Acquisition
Larka is delighted to announce it acted as the buy-side Commercial Due Diligence advisor for Apax Partners, supporting its acquisition of Porsolt, a leading French Contract Research Organization (CRO).
Merger & Acquisition
Larka is delighted to announce it acted as the sell-side Vendor Commercial Due Diligence provider to support the sale process of Albumedix – a leading recombinant albumin-based solution provider based in Nottingham, UK – acquired by the Sartorius Group.
Merger & Acquisition
Larka is delighted to announce it acted as the buy-side Commercial Due Diligence provider to support Keensight Capital on its acquisition of a majority stake in Axxam, a global-leading Contract Research Organization (CRO) based in Italy.
Merger & Acquisition
Larka is thrilled to announce it performed the Commercial Due Diligence to support Cathay Capital’s investment in TransCure bioServices, a global-leading Contract Research Organization (CRO) based in France.
Merger & Acquisition
Larka provides Merieux Equity Partners with a Commercial Due Diligence to support its investment in French BioPharma company Janvier Labs.
Merger & Acquisition
Larka provides Elyan Partners with a Commercial Due Diligence to support the acquisition of CRO services Business Unit of Oncodesign, a leading French BioPharma company.
Merger & Acquisition
Larka provides Gimv with a Technical Due Diligence and Operational Due Diligence to support its investment in leading Dutch bio-CDMO BioConnection.
Our People
Fresh out of college and hired amid the COVID-19 pandemic, Yana saw in Larka an opportunity to shape a career within the BioPharma industry while evolving in a fast-paced and exciting environment.
Merger & Acquisition
Larka is very pleased to announce that it’s M&A Unit performed the Vendor Commercial Due-Diligence to support Afinum’s exit process of evitria, a global leading service provider specialized in transient antibody expression.
Merger & Acquisition
Larka is very proud to announce that it performed the Commercial-Due-Diligence for Keensight Capital on its acquisition of Symeres.
Merger & Acquisition
Larka is pleased to announce that it performed the Commercial Due-Diligence for Clean Biologics group – backed by Archimed - on their acquisition of Biodextris.
Corporate News
As a result of a strong and continued growth in recent years, we are delighted to announce the opening of our new office in Nice.
Merger & Acquisition
Larka is pleased to announce that it performed the Commercial Due-Diligence, Operational Due-Diligence and Technical Due-Diligence for Cathay Capital.
Merger & Acquisition
Larka is pleased to announce that it performed the Commercial Due-Diligence, Operational Due-Diligence and Technical Due-Diligence for Keensight Capital.
Report
Larka is pleased to announce that it performed the Commercial Due-Diligence, Operational Due-Diligence and Technical Due-Diligence for Archimed.
Merger & Acquisition
Larka is pleased to announce that it performed the Commercial Due-Diligence, Operational Due-Diligence and Technical Due-Diligence for Keensight Capital and ERES, the new shareholders of Biovian.